Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Post-marketing, Observational Study to Evaluate the Safety and Effectiveness of Upadacitinib in Chinese Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT05959083 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05959083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05959083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Post-marketing, Observational Study to Evaluate the Safety and Effectiveness of Upadacitinib in Chinese Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
August 18, 2023
Completion date
May 7, 2026
Enrollment
200 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)